Speech-Language Pathologists in Anthony, NM Accepting Medicare
6 Speech-Language Pathologists found. Showing 1 - 6
 Ashlie Danielle Vasquez Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 875 Mercantil Ave, Anthony, NM 88021 Phone: 575-874-3592 |
Elizabeth M Ortiz-limon Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1325 Washington St, Anthony, NM 88021 Phone: 575-882-6101 |
Heather M Ramirez Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1271 Anthony Dr, Anthony, NM 88021 Phone: 575-882-3401 |
Santana Pastran Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2100 Venadito Trail, Anthony, NM 88021 Phone: 575-571-1252 |
Griselda Murguia Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1271 Anthony Dr, Anthony, NM 88021 Phone: 575-882-3401 Fax: 575-882-3256 |
Ayzzar Telles Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1325 Washington St, Anthony, NM 88021 Phone: 575-882-6101 |
News Archive
Prenatal exposure to organophosphate pesticides linked to lower IQ in children
In a new study suggesting pesticides may be associated with the health and development of children, researchers at the University of California, Berkeley's School of Public Health have found that prenatal exposure to organophosphate pesticides - widely used on food crops - is related to lower intelligence scores at age 7.
New EVestG diagnostic technique aids in quick detection of mental and neurological illnesses
An innovative diagnostic technique invented by a Monash University researcher could dramatically fast-track the detection of mental and neurological illnesses.
First North American trial to evaluate the role of an aromatase inhibitor in the prevention of breast cancer
Today, a new clinical trial evaluating a novel approach to breast cancer prevention launched in the United States and Canada. Called the ExCel research study, this is the first North American clinical trial to evaluate the role of an aromatase inhibitor in the prevention of breast cancer.
Report describes cardiopulmonary arrest in infant following cyclopentolate eyedrops
Eyedrops administered to infants as part of routine outpatient retinopathy of prematurity (ROP) screening can have life-threatening consequences. A case report published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) describes cardiopulmonary arrest in a 27-week-old infant following administration of three sets of cyclopentolate 0.2%/phenylephrine 1% (Cyclomydril) eyedrops.
Diamyd Medical announces share capital and total number of shares as of January 29, 2010
As of January 29, 2010, the share capital in Diamyd Medical AB (publ.) is 14 330 494 SEK. The total number of votes is 4 160 187 and the total number of shares is 28 660 988, divided among 1 437 876 shares of series A (1 vote) and 27 223 112 shares of series B (1/10 vote).
› Verified 8 days ago
Speech-Language Pathologists
Chiropractors
Occupational Therapists
Physical Therapists